Viral alcoholic and fatty liver diseases

Abstract

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections, alcohol, and non-alcoholic fatty liver disease (NAFLD) are major risk factors in the development of chronic liver disease (CLD), cirrhosis, and hepatocellular carcinoma (HCC). Various estimates have been proposed regarding the global prevalence of HBV and HCV carriers. According to a recent Polaris Observatory HCV Collaborators and the World Health Organization (WHO) burden estimates that 257 and 71 million people are living in the world with HBV and HCV infection, respectively, leading to an annual death from cirrhosis/liver failure and HCC of ~900,000 and ~400,000, respectively. Alcohol consumption, which is a major risk factor for CLD and HCC, is responsible for about 3.3 million deaths annually worldwide and for 5.1% of the global burden of disease as measured in disability-adjusted life years (DALYs). In recent years NAFLD and non-alcoholic steatohepatitis (NASH) associated with the metabolic syndrome, have captured the attention of hepatologists, public health experts, and the pharma industry alike. Indeed, the incidence of NAFLD and NASH and its complications including cirrhosis and HCC, is rising to epidemic proportions in the Western population, and constitute a major health problem worldwide.